Stockreport

IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

Imunon, Inc.  (IMNN) 
PDF Investor event in New York City to provide update on pivotal Phase 3 study of IMNN-001; offering in-person or virtual attendance on November 10, 2025 Program will featu [Read more]